Sygnature Discovery (Canada)

Sygnature Discovery (Canada) is the Canadian operation of Sygnature Discovery, a contract research organisation (CRO) that provides integrated drug discovery services to biotechnology and pharmaceutical companies. The parent company was founded in the United Kingdom in 2004 by Dr Simon Hirst, originally as Sygnature Chemical Services, and later renamed Sygnature Discovery in 2011 after the creation of its Bioscience department. The Canadian entity is based in Montreal and forms part of the group's North American presence, complementing its established operations in Europe. Sygnature Discovery works as an extension of its customers' research teams, offering expertise across the full range of preclinical drug discovery. Its services span medicinal and synthetic chemistry, bioscience, DMPK, pharmacology, and integrated drug discovery programmes that take a project from target identification through to candidate selection and preclinical development. The company emphasises that it has no internal pipeline of its own, so it is entirely focused on customer programmes and confidentiality. Its scientists are supported by artificial intelligence, automation, and high-throughput chemistry capabilities. The group reports more than 700 scientists from over 50 countries, working across Europe and North America. It states that it has contributed to over 60 advanced drug candidates and filed more than 200 patents, with over 200 active projects and a customer retention rate above 90%. Its client base ranges from small biotechnology companies racing to the clinic to large pharmaceutical companies seeking specialised expertise for targeted challenges. The Canadian site in Montreal is part of Sygnature Discovery's strategy to unite technologies, disciplines, and talent across Europe and North America. The company has established collaborations with AI and data-driven drug discovery firms, including X-Chem and DaltonTx, and has contributed to the early discovery of relacorilant, which received FDA approval as Lifyorli for ovarian cancer. Sygnature Discovery remains a private company and continues to expand its integrated drug discovery offering globally.

Sygnature Discovery was founded in August 2004 by Dr Simon Hirst under the name Sygnature Chemical Services, initially providing medicinal and synthetic chemistry services. The name "Sygnature" combines "synthesis" and "nature," reflecting Dr Hirst's vision of incorporating green chemistry principles. Dr Hirst had previously worked in large and mid-sized pharmaceutical companies, where he experienced frustration with the quality of outsourced drug discovery services, particularly regarding skills, infrastructure, communication, and project control. He established the company to offer a better model for drug discovery outsourcing. In September 2011, with the creation of its Bioscience department, the company was renamed Sygnature Discovery to better reflect its ability to design, synthesise, and test novel compounds in an integrated way throughout the drug discovery process. This marked a shift from a chemistry-focused service provider to a fully integrated drug discovery CRO. Over the following decade, Sygnature Discovery expanded its capabilities and scale. It grew to employ more than 700 scientists from over 50 countries, working across Europe and North America. The company reported contributions to over 60 advanced drug candidates, more than 200 patents filed, and over 200 active projects, with a customer retention rate above 90%. It invested in high-throughput chemistry facilities, including a £1 million enhancement, and adopted AI and automation to support its scientific work. The company also established a North American presence, including an operation in Montreal, Canada, which is the subject of this entry. This Canadian entity forms part of Sygnature Discovery's strategy to unite technologies, disciplines, and talent across Europe and North America. The group has formed collaborations with data-driven and AI drug discovery companies such as X-Chem and DaltonTx, and has contributed to the early discovery of relacorilant, which was later approved by the FDA as Lifyorli for ovarian cancer. As of the mid-2020s, Sygnature Discovery remains a private company focused exclusively on contract drug discovery services, with no internal pipeline.

• 2011

  Company renamed Sygnature Discovery in September following the creation of its Bioscience department.

• 2004

  Sygnature Chemical Services founded by Dr Simon Hirst in August, providing medicinal and synthetic chemistry services.

• Sygnature Discovery establishes DEL screening collaboration with X-Chem.

• Sygnature Discovery announces strategic collaboration with DaltonTx to advance AI-enabled drug discovery.

• Sygnature Discovery contributes to early discovery of relacorilant, later FDA-approved as Lifyorli for ovarian cancer.

• Sygnature Discovery completes major enhancement of high-throughput chemistry facilities following £1 million investment.

World-leading drug discovery solutions, accelerating compounds to the clinic, with no internal pipeline and total focus on customer success.

• Integrated Drug Discovery

  Fully integrated drug discovery programmes from target identification to pre-clinical development.

• Scientific Solutions

  Flexible scientific expertise and services across every discipline in preclinical discovery.

1. 1Sygnature Discovery - Leading Contract Research Organisationsygnaturediscovery.com
2. 2Sygnature Discovery History: Milestones Since 2004sygnaturediscovery.com
3. 3About Sygnature Discovery | Purpose, Mission and Valuessygnaturediscovery.com
4. 4Drug Discovery News & Events | Sygnature Discoverysygnaturediscovery.com
5. 5Sygnature Discovery (Canada) - Wikidatawikidata.org